Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an update.
Atomo Diagnostics Ltd. reported significant commercial progress in Q4 FY25, highlighted by a strategic partnership with Lumos Diagnostics for the Pascal FebriDx test in the U.S. market, which may lead to substantial revenue growth. The company also saw a 143% increase in Australian HIV Self-Test sales, reflecting a growing market for sexual health self-testing. Additionally, Atomo secured $2.6 million in new capital to support its operations and product development, and completed a board renewal process to enhance its strategic focus.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and commercialization of point-of-care testing solutions. The company is known for its innovative diagnostic products, including the Pascal test cassette used in various rapid tests, and has a significant presence in the HIV self-testing market.
Average Trading Volume: 989,559
Technical Sentiment Signal: Hold
Current Market Cap: A$13.39M
For an in-depth examination of AT1 stock, go to TipRanks’ Overview page.